This inventor holds 1 USPTO granted patent. Top assignees: Affymetrix, Inc., Genisphere, LLC. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 561 
1 out of 14 Years Active: 2017
Title: Innovator Jeremy N. Gollub: Pioneering Circulating miRNA Biomarker Research
Introduction: Jeremy N. Gollub is an accomplished inventor based in Palo Alto, California, known for his significant contributions to the field of biomarker research. With one patent to his name, Gollub's work focuses on the diagnosis and surveillance of complex multi-factorial disorders, such as cancer, using easily accessible biomarkers.
Latest Patents: Gollub's notable patent, titled "Circulating miRNA Biomarker Signatures," has introduced innovative methods for diagnosing and monitoring disorders by screening highly stable cell-free circulating nucleic acids (CNA) found in human blood and plasma. His findings establish strong correlations between tumor-associated genomic, epigenetic, and transcriptional changes alongside alterations in CNA levels, which are promising indicators for clinical applications. The patent emphasizes the use of microRNAs (miRNAs), a class of small non-coding RNAs, as markers for tracking specific expression profiles tied to cancer development. In addition, the patent outlines methods for isolating plasma fractions for the analysis of miRNA biomarkers and the measurement of circulating miRNA levels.
Career Highlights: Throughout his career, Gollub has worked with esteemed organizations such as Affymetrix, Inc., and Genisphere, LLC. His experience in these companies has played a vital role in advancing his research and understanding of complex molecular diagnostics.
Collaborations: Gollub's work has led him to collaborate with notable peers, including Radharani Duttagupta and Keith W. Jones. These collaborations have enriched his research efforts and amplified the impact of his contributions to the field.
Conclusion: Jeremy N. Gollub's innovative patent on circulating miRNA biomarkers marks a significant advancement in the early detection and monitoring of cancer and other complex disorders. His extensive experience and collaborations continue to pave the way for future breakthroughs in biomarker research, underscoring his role as a key figure in this important area of study.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile